Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Coronavirus infections are climbing again, marking another summer wave as children go back to school. But this uptick arrives with an added layer of uncertainty because it’s unclear when and which ...

The medical world relies on horseshoe crab blood in the production of vaccines and equipment. A synthetic is available, but ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...